资源描述：
《vp-16联合ddp心包腔内注射治疗非小细胞肺癌恶性心包积液》由会员上传分享，免费在线阅读，更多相关内容在教育资源-天天文库。
1、VP-16联合DDP心包腔内注射治疗非小细胞肺癌恶性心包积液《癌症》ChineseJournalofCancer,2006,25(4):505—508505VP.16联合DDP心包腔内注射治疗非小细胞肺癌恶性心包积液.1】盏床研究?陈丽昆?一,徐光川1,2梁颖.一,杨群英1,2,张利娜,IntrapericardialInfusionofEtoposideandCisplatininTreatingMalignantPericardialEffusionofNon?smallCellLungCancerCHENLi—Kun'?,X
2、UGuang—Chuan'?,LIANGYing',,YANGQun—Ying'',ZHANGLi—Na'?1.华南肿瘤学国家重点实验室.广东广州5100602.中山大学肿瘤防治中心内科.广东广州510060J.StateKeyLaboratoryofOrwologyinSouthChina,Guangzhou,Guangdong,510060,P.R.China2.DepartmentofMedicalOncology,CancerCen~r,SunYat—senUniversity,Guangzhou,Guangdong,51
3、0060,P.R.Ch.ina通讯作者:陈丽昆Correspondenceto:CHENLi—KunTel:86-20—87343368E—mail:ssnow2005@163.cola收稿日期:2005.09.19修回日期:2005.10.28[ABSTRACT]BACKGROUND&OBJECTIVE:PericardiocentesisandintraDericardiaIinfusionofchemotherapeuticdrugsiSthemaintreatmentofmalignantpericardialef
4、fusion.ThisstudywastoobservetheefficacyandsideeffectofintrapericardiaIinfusionofetoposide(VP一16)andcisplatin(DDP)onmalignantpericardialeffusionofnon—smallcelllungcancer(NSCLC).METHODS:Twenty—eightNSCLCpatientswithmalignantpericardialeffusionweretreatedwithpericardiOce
5、ntesisandintrapericardiaIinfusionofVP一16(200-300mg)andDDP(80—100mg).Intravenouschemotherapyweregiven2weeksafterthepericardiOcentesis.RESULTS:TheoveralIresponse(OR)rateofthefirst—timetreatmentofthe28patientswas85-7%.withcompleteresponse(CR)rateof71.4%:theORrateofthesec
6、ond—timetreatmentwas100%.Only4patientsneededsecond—timeDericardiOcentesis.Sixteenpatientsdevelopedgastrointestinaltractreaction(mainlygradeI—l1),12developedmyeIosuppression(mainlygradeI),and1showedmildabnormaloftransaminase.Forthe24nativepatients.theoverallsurvivaltim
7、ewas14monthsforstageⅢBand10.9monthsforstageIV:whereasforthe4patientswithrelapseddisease.theoverallsurvivaltimewas6months(fromthetimeofrelapse).CONCLUSION:IntrapericardialinfusionofVP一16andDDPiSaneffectivetreatmentformalignantpericardialeffusionofNSCLC.KEYWORDS:Lungneo
8、plasm;Malignantpericardialeffusion:ChemotherapyEtoposide:Cisplatin【摘要】背景与目的:心包穿刺抽液后心包腔内药物治疗是治疗恶性心包积液的主要手段.本研究观察足叶乙甙(VP.16)联合
